Sort   by:  
 Page size 
GenomicsTherapeutic genetics and disease modeling in LAMA2-CMD
Therapeutic genetics and disease modeling in LAMA2-CMD
PRJNA951467 | ENA
GenomicsTherapeutic genetics and disease modeling in LAMA2-CMD
Therapeutic genetics and disease modeling in LAMA2-CMD
PRJNA951468 | ENA
MetabolomicsDietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism

Ferroptosis is mediated by lipid peroxidation of phospholipids containing polyunsaturated fatty acyl moieties. Glutathione, the key cellular antioxidant capable of inhibiting lipid peroxidation via the activity of the enzyme glutathione peroxidase 4 (GPX-4), is generated directly from the sulfur-...

2023-01-11 | MTBLS5959 | MetaboLights
GenomicsEfficient LAMA1 gene activation by epigenome editing as a therapeutic 2 approach for LAMA2-CMD
Efficient LAMA1 gene activation by epigenome editing as a therapeutic 2 approach for LAMA2-CMD
PRJNA1273989 | ENA
UnknownDevelopment of DNA markers for assisted selection of cassava resistant to cassava mosaic disease (CMD).
Not available
S-EPMC12395196 | biostudies-literature
TranscriptomicsmicroRNA profiling of muscular dystrophies
In this study, we aim to identify common miRNA signatures in the pathogenesis of different NMD groups (Duchenne Muscular Dystrophy, Megaconial Congenital Muscular Dystrophy (CMD), Ullrich CMD and alpha-dystroglycanopathy) (abbreviated as D, M, U, and A, respectively) each caused by mutations in diff...
ORGANISM(S): Homo sapiens 
2020-06-22 | E-MTAB-9030 | biostudies-arrayexpress
UnknownEffect of enhanced external counterpulsation on coronary microcirculation dysfunction (CMD) in patients with coronary artery disease (EECP-CMD II): study protocol of a single-centre, open-label, parallel group, randomised controlled trial.
Not available
S-EPMC11404164 | biostudies-literature
TranscriptomicsEfficient LAMA1 gene activation by epigenome editing as a therapeutic 2 approach for LAMA2-CMD
Epigenome editing technology holds great promise for treating diverse genetic disorders. Here we demonstrate epigenetic activation of the LAMA1 gene for the treatment of LAMA2-CMD, a severe congenital muscular dystrophy (CMD) caused by biallelic mutations in the LAMA2 gene. LAMA1 is a sister homolog...
ORGANISM(S): Mus musculus 
2026-06-01 | GSE299372 | GEO
UnknownAbsence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD.
Not available
S-EPMC5542641 | biostudies-literature
GenomicsMuscle miRNAs in LAMA2-CMD
Profiling skeletal muscle microRNAs in laminin alpha 2 chain-deficient congenital muscular dystrophy
PRJEB24388 | ENA
Sort   by:  
 Page size